ArticleInflammation2026
Single-Cell Transcriptomics Identifies a Pivotal Role of SPHK1
Article in Inflammation, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
Macrophages are a key heterogeneous cell population involved in the pathogenesis and progression of acute aortic dissection (AD), though their mechanisms remain unclear. This study aims to identify the gene driving inflammatory damage in acute AD within a specific macrophage subcluster, highlighting potential therapeutic targets. Single-cell RNA sequencing (scRNA-seq) was employed to analyze the cellular heterogeneity in acute AD and normal aortic tissues. Bioinformatic analysis was conducted to identify the key gene. The role of sphingosine kinase 1 (SPHK1) was further explored using human acute AD tissue samples, macrophage cell line experiments, and AD mouse models. scRNA-seq identified six macrophage subclusters in AD tissues, with subcluster a exhibiting a pronounced pro-inflammatory phenotype. SPHK1 was significantly upregulated in this subcluster and was identified as the key regulatory gene. In vitro, inhibition of SPHK1 reduced macrophage-mediated inflammatory damage via the S1P-S1PR2/3-RhoA-ROCK1 signaling pathway. In vivo studies revealed a 40% reduction in the incidence of AD and significantly reduced severity in mice treated with PF-543 (a specific SPHK1 inhibitor). In this model, PF-543 reduced macrophage infiltration and the inflammatory damage caused by inflammatory factors and matrix metalloproteinases. This study identifies macrophage-driven inflammation, particularly via SPHK1, as a central mechanism in AD. Targeting SPHK1 and the associated S1P-S1PR2/3-RhoA-ROCK1 signaling pathway offers a potential therapeutic strategy for mitigating AD progression.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.